0000899243-20-002069.txt : 20200127 0000899243-20-002069.hdr.sgml : 20200127 20200127180212 ACCESSION NUMBER: 0000899243-20-002069 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200123 FILED AS OF DATE: 20200127 DATE AS OF CHANGE: 20200127 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rickey James Paul CENTRAL INDEX KEY: 0001606243 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37449 FILM NUMBER: 20550907 MAIL ADDRESS: STREET 1: C/O IMMUNE DESIGN CORP. STREET 2: 1616 EASTLAKE AVE. E, SUITE 310 CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALPINE IMMUNE SCIENCES, INC. CENTRAL INDEX KEY: 0001626199 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208969493 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 188 EAST BLAINE ST., SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-788-4545 MAIL ADDRESS: STREET 1: 188 EAST BLAINE ST., SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Nivalis Therapeutics, Inc. DATE OF NAME CHANGE: 20150211 FORMER COMPANY: FORMER CONFORMED NAME: N30 Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20141121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-01-23 0 0001626199 ALPINE IMMUNE SCIENCES, INC. ALPN 0001606243 Rickey James Paul C/O ALPINE IMMUNE SCIENCES, INC. 188 EAST BLAINE STREET, SUITE 200 SEATTLE WA 98102 0 1 0 0 Senior VP and CFO Common Stock 2020-01-23 4 A 0 18543 0.00 A 28543 D Stock Option (right to buy) 3.23 2020-01-23 4 A 0 102000 0.00 A 2030-01-22 Common Stock 102000 102000 D Received a grant of restricted stock units ("RSUs") pursuant to the 2018 Equity Incentive Plan for no consideration. The RSUs were granted in lieu of a portion of cash incentive compensation achieved pursuant to the terms of the Company's Executive Incentive Compensation Plan. Fifty percent (50%) of the RSUs will vest on June 30, 2020 and fifty percent (50%) of the RSUs will vest on December 31, 2020, subject to the Reporting Person continuing to be a Service Provider through each such date. The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of January 23, 2020 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date. /s/ James Paul Rickey 2020-01-27